Tran Ngo Minh Anh, born in 2002 and the daughter of Nam A Bank Chairman Tran Ngo Phuc Vu, has been appointed General Director of Ben Tre Pharmaceutical JSC (Bepharco, ticker DBT, HoSE) effective November 1, 2026. She became a board member and Deputy General Director on July 30, 2026, replacing Nguyen Khac Hanh, who resigned after just over three months in the role. She holds a finance degree from the University of Central Florida and worked at New Omni Bank in California, US, during 2024-2026, and she currently owns no DBT shares. DBT also approved a stock dividend issuance at a 7% ratio (100:7), equal to 1.53 million new shares, which would raise charter capital from VND 219.6 billion to nearly VND 235 billion once completed.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Con gái Chủ tịch Nam A Bank làm Tổng giám đốc Dược phẩm Bến Tre
Keywords
DBTpharmaceuticalsdividendscorporate governance
Open a keyword to see other news on the same topic.
Related tickers and likely impact
NAB
• NeutralNam A Bank
Relevance: low
| Market | Vietnam stocks |
|---|---|
| Exchange | HOSE |
| Sector | Banks |
| Market cap | 26,446 bn VND |
| P/E | 5.6 |
| P/B | 1.02 |
| Close on 10/23/2026 | 12.60 |
| Change that session | +2.86% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- Daughter of Nam A Bank chairman, 24, becomes CEO of pharmaceutical firm
Tran Ngo Minh Anh, born in 2002, is the daughter of Tran Ngo Phuc Vu, chairman of the board of Nam A Bank. She was appointed CEO of Ben Tre Pharmaceutical JSC (DBT) from early November, only three months after becoming deputy CEO. The appointment followed the company's approval, on the afternoon of October 23, of the resignation of Nguyen Khac Hanh as CEO. Minh Anh holds a bachelor's degree in finance from the University of Central Florida and worked at New Omni Bank in California, USA, during 2024-2026; she currently holds no DBT shares. In 2025, the company reported revenue of VND 860 billion, and in the first half of this year it reached about VND 420 billion. DBT shares trade around VND 13,000.
- Bến Tre Pharmaceutical Appoints Female General Director
Bepharco announced the appointment of Ms. Trần Ngô Minh Anh (24) as general director under a decision dated October 23, 2026, effective November 1, 2026. Ms. Minh Anh earned a finance degree from the University of Central Florida on a scholarship and then spent nearly three years at New Omni Bank (NOB), a California-based bank. She joined Bepharco in August, was elected to the board at the 2026 extraordinary general meeting, and was later named deputy general director before this appointment. Founded in 1963, the pharmaceutical company's shares trade under the ticker DBT.
- What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer
The article argues that rising interest rates could make the high dividend yields of pharmaceutical stocks such as Pfizer and AbbVie less appealing, since the 10-year U.S. Treasury yield serves as the benchmark for comparing income investments. The Federal Reserve raised rates by 25 basis points last month after a series of cuts in 2024 and 2025, and numerous economists expect further hikes. Pfizer, with a 5.7% dividend yield, has several top products approaching patent expiration and is in a slow reset phase, while AbbVie's 2.4% yield is supported by growth from Skyrizi and Rinvoq. The author expects rising rates to pressure Pfizer's stock more than AbbVie's, though he remains bullish on both companies.
- Great News for AbbVie Stock Investors
AbbVie (ABBV) shares have climbed 26% this year on strong financial performance, and the author sees a bright medium-term outlook. Skyrizi, the company's biggest growth driver, generated almost $10 billion in sales in the first half, up 27%, but its U.S. patents may begin expiring by 2033, potentially opening the door to cheaper biosimilars. On Oct. 19, AbbVie reported encouraging Phase 2a results for ABBV-466, which combines risankizumab and trosunilimab, though these must still be confirmed in Phase 3 studies. Its $10.9 billion cash acquisition of Apogee Therapeutics brought zumilokibart, which AbbVie hopes can challenge Dupixent (over $15 billion in annual sales), with maintenance injections possibly only every three or six months. Rinvoq should not face U.S. generics until 2037, and the author says AbbVie can deliver competitive long-term returns, with a forward yield of 2.5% versus the S&P 500's average of 1.1%.
- 3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
The article argues that Royalty Pharma suits buy-and-hold income investors for three reasons: healthcare spending tends to stay resilient through economic cycles, the company's experts select which drugs to back, and its portfolio is diversified. Royalty Pharma pays drug companies cash up front in exchange for future royalties on approved and in-development drugs, and that cash funds its shareholder distributions. Its yield is around 1.5%, slightly above the pharmaceutical sector average of roughly 1.4%. The portfolio includes 35 approved products and 16 in development, with 16 generating more than $1 billion in annual revenue and an average remaining royalty duration of around 13 years. The article acknowledges that some of its drug investments will not work out as planned.
- Johnson & Johnson Raised Its Dividend Every Year. Why Did It Trail the S&P 500?
Johnson & Johnson (NYSE:JNJ) has raised its dividend for 64 straight years, yet a plain S&P 500 index fund beat the stock over the past decade. A $1,000 investment 10 years ago with reinvested dividends would be worth $2,957.10 today, about $703 of it from dividends, versus $3,593.10 for the S&P 500 over the same period, excluding dividends. In the third quarter of 2026, about $7 billion in charges for a proposed talc settlement and two deals cut reported EPS to $0.09, while adjusted EPS was $2.59. The company expects $21 billion in free cash flow this year, but net debt is about $28 billion, and two recent deals are expected to cut 2027 adjusted EPS by $1.36; the article warns that if talc payments eat into free cash flow, dividend increases could shrink.
Related markets
Latest news
- Apple's new hardware push is meeting AI-worried investors at the right moment
Apple is pushing its hardware lineup to reclaim the title of the most valuable company on the stock market, briefly succeeding on Friday. The campaign, led by new CEO John Ternus, marks a shift from predecessor Tim Cook's services-first strategy and comes as the AI trade loses steam. Investor concerns over AI financing were renewed this week by Meta's off-balance-sheet spending plans of $825 billion and Tesla's estimated $100 billion chip plant, while SK Hynix paused a spin-off IPO and the 10-year Treasury yield pushed back under 5%. The new iPhone Duo launched Friday.
- Trump threatens new 'Epic Fury' military campaign against Iran
U.S. President Donald Trump on October 23 threatened a further military campaign against Iran as Washington pulls diplomatic staff and troops out of the Middle East. The State Department is cutting staff at 4 more embassies in the region, while the Pentagon is reportedly moving troops from bases in Jordan, Qatar and Kuwait. According to reports, the Pentagon has presented Trump with new strike options against nuclear sites, underground military facilities and strategic islands, including Kharg, though U.S. officials deny the staff cuts are linked to attack preparations. Trump pledged no new attacks before the November 3 midterm elections but did not rule out using military force if Tehran refuses Washington's demands.
- Chief Accountant Hid Stock Trading for Nearly 14 Years
The State Securities Commission has announced fines totaling 450 million VND for two executives of CMH Vietnam Group Joint Stock Corporation (CMS): Deputy General Director Trần Văn Trung and Chief Accountant Đinh Thị Thủy, 225 million VND each. Both were found to have traded CMS shares through securities accounts registered in others' names, concealing their true ownership and evading information disclosure obligations. Trung's violation period lasted over 1.5 years, while Thủy's lasted nearly 14 years. The penalty decisions took effect on October 20, 2026.
- History Says Nvidia Rarely Trades This Cheaply. Here's What Happened the Last Time.
Nvidia shares trade at 23 times fiscal 2027 earnings, below the five-year average forward earnings multiple of 33.4 according to Morningstar, and have risen 19% in 2026 versus 62% for the PHLX Semiconductor index. First-half fiscal 2027 revenue rose 96% year over year to $177.8 billion, while non-GAAP earnings per share climbed 130% to $4.09. The 12-month median price target is $320, about 44% above current levels. The author outlines a scenario in which, at 30 times earnings at the end of fiscal 2029 and EPS of $21.34, the stock could reach $640. The last time Nvidia's forward earnings multiple was below 20 was at the end of 2018, when it stood at 18.7.
- Prediction: Here’s Where SpaceX Stock Will Trade on Its 1-Year IPO Anniversary
SpaceX’s IPO on June 12, 2026, was the largest in stock market history, and its shares trade near the IPO price nearly five months later. Key events before June 12, 2027 include quarterly earnings, a full 180-day lockup expiring on Dec. 8, 2026, and Elon Musk being able to sell his 6.4 billion shares on June 12, 2027. Musk has said SpaceX and Tesla are exploring a merger, though not a done deal, and SpaceX could be eligible for S&P 500 inclusion in mid-2027 if it shows profitability. The author outlines a bull case of $220–$240, a base case of $165–$185 and a bear case of $90–$110, and predicts about $200 on June 12, 2027. The consensus 12-month price target is $240.
- I'm Calling It: Bloom Energy Will Be the Biggest Winner of the AI Power Crunch for 1 Reason
The author argues Bloom Energy (BE) will benefit most from AI’s power shortage because its solid oxide fuel cells can bring data centers online in about three months without grid connections, unlike utility hookups that can take years. Bloom crossed $1 billion in revenue in the second quarter, up 166% year over year, and holds about $2.7 billion in cash. Management raised full-year revenue guidance to $3.9 billion–$4.2 billion, nearly double 2025 levels. Shares have risen more than 150% year to date and trade at 357 times trailing earnings, which the author believes is justified by the improving balance sheet and steady demand for fast power.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.